IRB Barcelona is to hold three workshops for all kinds of public
The health-specialized site Jano.es has dedicated an article to a new study published in Developmental Cell by Marco Milán, ICREA researcher and leader of the Development and Growth Control Laboratory at IRB Barcelona. The paper explains how protective cellular mechanisms triggered by aneuploidy could cause tumours.
Aneuploid cells—that is to say those with an abnormal number of chromosomes—are found in most human tumours.
A study conducted at IRB Barcelona on the fly Drosophila reveals how surviving aneuploid cells favour tumour development.
Diari de Girona has published a column on a new mechanism involved in tissue regeneration, discovered recently. The study, published in PLOS Genetics, was conducted by the Department of Genetics at the University of Barcelona in collaboration with the group led by Marco Milán, ICREA researcher and leader of the Development and Growth Control Laboratory group at IRB Barcelona. This new mechanism is a significant advance in understanding how tissue regeneration works, and indicates that antioxidants may have a negative effect during the early stages of this process.
Various media, including the newspaper “El Punt Avui”, have echoed the study published in PLoS Biology by Marco Milán, ICREA researcher and group leader of the Development and Growth Control Laboratory at IRB Barcelona, and Ana Ferreira, PhD student from the same laboratory. The researchers have explained the way tumour suppressor genes regulate the growth of cells surrounding the tumour.
Researchers at IRB Barcelona unravel a role for tumour suppressor genes in restricting the growth of neighbouring cell populations.
The study, published yesterday in PLoS Biology, might have implications for understanding the early events of tumorigenesis and the selection of the tumour-initiating cells.
The newspaper “El Periódico de Catalunya” has echoed the award ceremony of the 77 grants given by the “Obra Social La Caixa” foundation to support doctoral students. This grant programme aims to retain Spanish students and attract international students with talent for research, both for Spanish universities and Severo Ochoa centres. In this edition, IRB Barcelona students Jürgen Walther, Craig Donoghue, Elzbieta Szulc, and Lada Murcia received these awards.
“El País” newspaper has published an article on the Barcelona BioMed Conference “Drosophila as a model in cancer”. It includes statements made by Marco Milán, ICREA researcher and head of the Development and Growth Control Laboratory, and Cayetano González, ICREA researcher and head of the Cell Division Laboratory, both at IRB Barcelona and co-organizers of this scientific meeting, which is supported by the BBVA Foundation.
The article highlights the project presented by Ross Cagan, director of the Center for Personalized Cancer Therapeutics at Mount Sinai Hospital (United States), which uses flies that have the same tumours as those found in human patients to design personalized...
Various media have echoed the news about the Barcelona BioMed Conference on the use of the fly Drosophila melanogaster as a model to study cancer. Organised by IRB Barcelona with the support of the BBVA Foundation, the meeting will take place from 15 to 17 June in Barcelona. Marco Milán, ICREA researcher and head of the Development and Growth Control Laboratory, and Cayetano González, ICREA researcher and head of the Cell Division Laboratory, both at IRB Barcelona, have selected the 23 speakers who will participate in the conference.
In the conference “Drosophila as a model in cancer”, to be held from 15 to 17 June in Barcelona, IRB Barcelona and the BBVA Foundation bring together a select group of leading scientists that use the fruit fly for cancer research.
This fly can be used to study specific types of tumour, ranging from leukaemia to brain tumours, and complex processes such as metastasis or the wasting syndrome (extreme muscle weakness) associated with cancer. In addition, Drosophila has proved to be an excellent tool for drug screening in vivo.
Nobert Perrimon is among the invited speakers. From his lab at Harvard, he has performed one of the largest screenings of molecules in flies in search of new anti-tumour applications of drugs that have already been approved by the FDA.
Special mention is also given to the participation of Sam Jackson, from the National Center for the Replacement, Refinement and Reduction of Animals in Research, a British organisation that promotes and supports the use of invertebrate models, such as Drosophila, for cancer research.